Medical - Devices
Compare Stocks
4 / 10Stock Comparison
VMD vs ISRG vs HOLX vs NVCR
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
Medical - Instruments & Supplies
Medical - Instruments & Supplies
VMD vs ISRG vs HOLX vs NVCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||||
|---|---|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies | Medical - Instruments & Supplies | Medical - Instruments & Supplies |
| Market Cap | $353M | $161.07B | $16.97B | $1.92B |
| Revenue (TTM) | $287M | $10.58B | $4.13B | $674M |
| Net Income (TTM) | $15M | $2.98B | $544M | $-173M |
| Gross Margin | 57.5% | 66.3% | 52.8% | 75.2% |
| Operating Margin | 8.2% | 30.5% | 17.5% | -27.2% |
| Forward P/E | 19.2x | 43.8x | 17.2x | — |
| Total Debt | $16M | $303M | $2.63B | $290M |
| Cash & Equiv. | $14M | $3.37B | $1.96B | $103M |
VMD vs ISRG vs HOLX vs NVCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Viemed Healthcare, … (VMD) | 100 | 110.6 | +10.6% |
| Intuitive Surgical,… (ISRG) | 100 | 234.6 | +134.6% |
| Hologic, Inc. (HOLX) | 100 | 142.6 | +42.6% |
| NovoCure Limited (NVCR) | 100 | 25.0 | -75.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VMD vs ISRG vs HOLX vs NVCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
VMD is the clearest fit if your priority is growth exposure.
- Rev growth 20.5%, EPS growth 32.1%, 3Y rev CAGR 24.9%
- 20.5% revenue growth vs HOLX's 1.7%
ISRG is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 5.5% 10Y total return vs VMD's 413.5%
- 28.2% margin vs NVCR's -25.7%
- 14.8% ROA vs NVCR's -16.5%, ROIC 15.0% vs -16.4%
HOLX carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.41
- Lower volatility, beta 0.41, Low D/E 52.0%, current ratio 3.75x
- Beta 0.41, current ratio 3.75x
- Better valuation composite
NVCR lags the leaders in this set but could rank higher in a more targeted comparison.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.5% revenue growth vs HOLX's 1.7% | |
| Value | Better valuation composite | |
| Quality / Margins | 28.2% margin vs NVCR's -25.7% | |
| Stability / Safety | Beta 0.41 vs NVCR's 2.20, lower leverage | |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | +37.1% vs ISRG's -15.4% | |
| Efficiency (ROA) | 14.8% ROA vs NVCR's -16.5%, ROIC 15.0% vs -16.4% |
VMD vs ISRG vs HOLX vs NVCR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
VMD vs ISRG vs HOLX vs NVCR — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ISRG leads in 3 of 6 categories
VMD leads 1 • HOLX leads 1 • NVCR leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
ISRG leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ISRG is the larger business by revenue, generating $10.6B annually — 36.9x VMD's $287M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to NVCR's -25.7%. On growth, VMD holds the edge at +27.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||||
|---|---|---|---|---|
| RevenueTrailing 12 months | $287M | $10.6B | $4.1B | $674M |
| EBITDAEarnings before interest/tax | $46M | $3.8B | $974M | -$165M |
| Net IncomeAfter-tax profit | $15M | $3.0B | $544M | -$173M |
| Free Cash FlowCash after capex | $26M | $2.8B | $1000M | -$48M |
| Gross MarginGross profit ÷ Revenue | +57.5% | +66.3% | +52.8% | +75.2% |
| Operating MarginEBIT ÷ Revenue | +8.2% | +30.5% | +17.5% | -27.2% |
| Net MarginNet income ÷ Revenue | +5.2% | +28.2% | +13.2% | -25.7% |
| FCF MarginFCF ÷ Revenue | +9.0% | +26.8% | +24.2% | -7.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +27.5% | +23.0% | +2.5% | +12.3% |
| EPS Growth (YoY)Latest quarter vs prior year | 0.0% | +18.8% | -9.2% | -100.0% |
Valuation Metrics
VMD leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 24.9x trailing earnings, VMD trades at a 57% valuation discount to ISRG's 57.6x P/E. On an enterprise value basis, VMD's 7.2x EV/EBITDA is more attractive than ISRG's 43.6x.
| Metric | ||||
|---|---|---|---|---|
| Market CapShares × price | $353M | $161.1B | $17.0B | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $356M | $158.0B | $17.6B | $2.1B |
| Trailing P/EPrice ÷ TTM EPS | 24.89x | 57.62x | 30.53x | -13.80x |
| Forward P/EPrice ÷ next-FY EPS est. | 19.19x | 43.84x | 17.21x | — |
| PEG RatioP/E ÷ EPS growth rate | — | 2.65x | — | — |
| EV / EBITDAEnterprise value multiple | 7.21x | 43.62x | 17.39x | — |
| Price / SalesMarket cap ÷ Revenue | 1.31x | 16.00x | 4.14x | 2.92x |
| Price / BookPrice ÷ Book value/share | 2.62x | 9.17x | 3.43x | 5.51x |
| Price / FCFMarket cap ÷ FCF | 29.59x | 64.67x | 18.44x | — |
Profitability & Efficiency
ISRG leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-51 for NVCR. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), HOLX scores 7/9 vs VMD's 4/9, reflecting strong financial health.
| Metric | ||||
|---|---|---|---|---|
| ROE (TTM)Return on equity | +10.5% | +16.9% | +11.0% | -50.8% |
| ROA (TTM)Return on assets | +7.5% | +14.8% | +6.1% | -16.5% |
| ROICReturn on invested capital | +11.6% | +15.0% | +9.4% | -16.4% |
| ROCEReturn on capital employed | +13.2% | +16.5% | +8.8% | -28.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 6 | 7 | 5 |
| Debt / EquityFinancial leverage | 0.11x | 0.02x | 0.52x | 0.85x |
| Net DebtTotal debt minus cash | $2M | -$3.1B | $667M | $187M |
| Cash & Equiv.Liquid assets | $14M | $3.4B | $2.0B | $103M |
| Total DebtShort + long-term debt | $16M | $303M | $2.6B | $290M |
| Interest CoverageEBIT ÷ Interest expense | 14.61x | — | 8.00x | -96.80x |
Total Returns (Dividends Reinvested)
ISRG leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ISRG five years ago would be worth $15,873 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, HOLX leads with a +37.1% total return vs ISRG's -15.4%. The 3-year compound annual growth rate (CAGR) favors ISRG at 14.4% vs NVCR's -37.6% — a key indicator of consistent wealth creation.
| Metric | ||||
|---|---|---|---|---|
| YTD ReturnYear-to-date | +27.6% | -19.3% | +1.9% | +28.3% |
| 1-Year ReturnPast 12 months | +26.7% | -15.4% | +37.1% | +1.1% |
| 3-Year ReturnCumulative with dividends | -14.6% | +49.6% | -8.5% | -75.7% |
| 5-Year ReturnCumulative with dividends | -3.8% | +58.7% | +15.8% | -91.3% |
| 10-Year ReturnCumulative with dividends | +413.5% | +554.2% | +124.3% | +30.3% |
| CAGR (3Y)Annualised 3-year return | -5.1% | +14.4% | -2.9% | -37.6% |
Risk & Volatility
HOLX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HOLX is the less volatile stock with a 0.41 beta — it tends to amplify market swings less than NVCR's 2.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HOLX currently trades 100.0% from its 52-week high vs ISRG's 75.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||||
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.95x | 1.02x | 0.41x | 2.20x |
| 52-Week HighHighest price in past year | $10.18 | $603.88 | $76.04 | $20.06 |
| 52-Week LowLowest price in past year | $5.93 | $427.84 | $52.81 | $9.82 |
| % of 52W HighCurrent price vs 52-week peak | +90.5% | +75.1% | +100.0% | +83.9% |
| RSI (14)Momentum oscillator 0–100 | 34.7 | 42.4 | 69.1 | 69.8 |
| Avg Volume (50D)Average daily shares traded | 312K | 1.8M | 10.0M | 1.5M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: VMD as "Buy", ISRG as "Buy", HOLX as "Hold", NVCR as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs 3.9% for HOLX (target: $79).
| Metric | ||||
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | — | $622.60 | $79.00 | $33.50 |
| # AnalystsCovering analysts | 1 | 55 | 42 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 2 | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +3.7% | +1.4% | +4.4% | 0.0% |
ISRG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). VMD leads in 1 (Valuation Metrics).
VMD vs ISRG vs HOLX vs NVCR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is VMD or ISRG or HOLX or NVCR a better buy right now?
For growth investors, Viemed Healthcare, Inc.
(VMD) is the stronger pick with 20. 5% revenue growth year-over-year, versus 1. 7% for Hologic, Inc. (HOLX). Viemed Healthcare, Inc. (VMD) offers the better valuation at 24. 9x trailing P/E (19. 2x forward), making it the more compelling value choice. Analysts rate Viemed Healthcare, Inc. (VMD) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — VMD or ISRG or HOLX or NVCR?
On trailing P/E, Viemed Healthcare, Inc.
(VMD) is the cheapest at 24. 9x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Hologic, Inc. is actually cheaper at 17. 2x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — VMD or ISRG or HOLX or NVCR?
Over the past 5 years, Intuitive Surgical, Inc.
(ISRG) delivered a total return of +58. 7%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus NVCR's +30. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — VMD or ISRG or HOLX or NVCR?
By beta (market sensitivity over 5 years), Hologic, Inc.
(HOLX) is the lower-risk stock at 0. 41β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 437% more volatile than HOLX relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — VMD or ISRG or HOLX or NVCR?
By revenue growth (latest reported year), Viemed Healthcare, Inc.
(VMD) is pulling ahead at 20. 5% versus 1. 7% for Hologic, Inc. (HOLX). On earnings-per-share growth, the picture is similar: Viemed Healthcare, Inc. grew EPS 32. 1% year-over-year, compared to -25. 0% for Hologic, Inc.. Over a 3-year CAGR, VMD leads at 24. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — VMD or ISRG or HOLX or NVCR?
Intuitive Surgical, Inc.
(ISRG) is the more profitable company, earning 28. 4% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is VMD or ISRG or HOLX or NVCR more undervalued right now?
On forward earnings alone, Hologic, Inc.
(HOLX) trades at 17. 2x forward P/E versus 43. 8x for Intuitive Surgical, Inc. — 26. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.
08Which pays a better dividend — VMD or ISRG or HOLX or NVCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is VMD or ISRG or HOLX or NVCR better for a retirement portfolio?
For long-horizon retirement investors, Hologic, Inc.
(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HOLX: +124. 3%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between VMD and ISRG and HOLX and NVCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: VMD is a small-cap high-growth stock; ISRG is a mid-cap high-growth stock; HOLX is a mid-cap quality compounder stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.